Causaly and Microsoft target one of drug discovery’s most expensive decisions: which target to pursue

At Microsoft Build 2026, the software giant’s annual developer conference, held June 2 and 3 in San Francisco, the life sciences AI company Causaly announced a collaboration with Microsoft aimed at one of drug discovery’s earliest and most consequential decisions: which biological targets are worth pursuing. Causaly runs an agentic AI platform that reads across… The post Causaly and Microsoft target one of drug discovery’s most expensive decisions: which target to pursue appeared first on Resear